Streetbeat News

Analyst Ratings

NUE

Nucor Corporation (NYSE:NUE) is set to release its Q3 earnings on Oct. 21, with expected earnings of $1.47 per share, down from $4.57 last year. Revenue is projected at $7.28 billion. JPMorgan has maintained an Overweight rating but lowered the price target to $170. Nucor offers a 1.37% annual dividend yield, translating to $2.16 per share annually. To earn $500 monthly from dividends, an investment of approximately $439,174 is needed.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 12:59 pm

NFLX

Jefferies analyst Andrew Uerkwitz maintains a Buy rating on Netflix and raises the price target from $780 to $800.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:58 pm

SHW

Morgan Stanley has maintained an Overweight rating on Sherwin-Williams and raised its price target from $375 to $450, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:54 pm

FLS

Jefferies analyst Saree Boroditsky has reinstated a Buy rating on Flowserve (NYSE:FLS) and set a price target of $65.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:52 pm

AMZN

Wedbush analysts suggest that Amazon's current underperformance presents a buying opportunity ahead of its Q3 earnings. Despite concerns over Project Kuiper costs, they maintain an Outperform rating and a $225 price target, expecting long-term margin growth driven by advertising and AWS revenue.

Portfolio Pulse from Benzinga Neuro

October 18, 2024 | 12:50 pm

ECL

Jefferies analyst Laurence Alexander has upgraded Ecolab (NYSE:ECL) from Hold to Buy and increased the price target from $235 to $310.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:50 pm

COFS

DA Davidson has initiated coverage on ChoiceOne Financial Services (NASDAQ:COFS) with a Buy rating and set a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:48 pm

AXP

American Express reported Q3 earnings with an 8% revenue growth, slightly missing estimates, but EPS beat expectations. Card spending increased, and the company revised its annual outlook. Despite initial stock gains, AXP shares fell premarket. The company faces downgrades from several analysts.

Portfolio Pulse from Anusuya Lahiri

October 18, 2024 | 12:28 pm

IGMS

RBC Capital analyst Brian Abrahams maintains an Outperform rating on IGM Biosciences and raises the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:27 pm

HBAN

RBC Capital analyst Jon Arfstrom has reiterated an Outperform rating on Huntington Bancshares (NASDAQ:HBAN) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:25 pm